New drug combo shows promise for tough head and neck cancers
NCT ID NCT03468218
First seen Jan 29, 2026 · Last updated May 01, 2026 · Updated 12 times
Summary
This study tests two drugs, pembrolizumab and cabozantinib, in people with head and neck cancer that has returned or spread and cannot be surgically removed. The goal is to see if the combination can shrink tumors or slow the cancer's growth. About 36 adults with advanced squamous cell carcinoma of the head and neck are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Emory University Hospital Midtown
Atlanta, Georgia, 30308, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.